



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

18 February 2010
EMA/CHMP/31616/2010
Committee for medicinal products for human use (CHMP)

Summary of opinion¹ (initial authorisation)

Humenza

Active substance: Split influenza virus, inactivated, containing antigen: A/California/7/2009 (H1N1)v like strain (X-179A)

Common name: Pandemic Influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)

On 18 February 2010 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion², recommending the granting of a conditional marketing authorisation for the medicinal product Humenza, 3.8 micrograms haemagglutinin per dose, suspension and emulsion for emulsion for injection intended for prophylaxis of influenza in an officially declared pandemic situation. The applicant for this medicinal product is Sanofi Pasteur SA. They may request a re-examination of any CHMP opinion, provided they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The active substance of Humenza is split influenza virus, inactivated, containing antigen: A/California/7/2009 (H1N1)v like strain (X-179A) an Influenza vaccine class medicinal product ATC Code J07BB02. This vaccine will be used for active immunization against the (H1N1)v 2009 influenza strain in an official declared influenza pandemic situation.

The benefits with Humenza are its ability to that it can mount an appropriate immune response in individuals that are immunologically naive against the pandemic strain A/California/7/2009 (H1N1)v. The most common side effects are injection site reactions, myalgia and headache.

A pharmacovigilance plan for Humenza will be implemented as part of the marketing authorisation.

The approved indication is: "Prophylaxis of influenza in an officially declared pandemic situation". It is proposed that Humenza is prescribed by physicians experienced in the treatment of influenza.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR), and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the commission decision, which will normally be issued 67 days from adoption of the opinion.



The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit to risk balance for Humenza and therefore recommends the granting of the marketing authorisation. The marketing authorisation is conditional³.

³ A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorisation holder is likely to provide comprehensive clinical data at a later stage.